Avelumab Program Rollover Study
The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.
Solid Tumors
DRUG: Avelumab
Occurrence of Treatment-related Non-serious Treatment-Emergent Adverse Events (TEAEs), All Serious AEs, Immunerelated AEs and Infusion-related Reactions According to Version of National Cancer Institute Common Technology Criteria for Adverse Events, From enrollment to end of survival follow-up (up to 5 years after the last participant receives the last dose of avelumab)
Overall Survival (OS), From baseline up to 5 years|Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), From baseline up to 5 years|Duration of Response (DOR) Assessed From Complete Response (CR) or Partial Response (PR), From baseline up to 5 years
The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.